In this study, a significant decrease in the mucin content of corpus mucosa was noted after oral administration of 5-FU at a dose of 50 mg/kg once daily for 5 consecutive days. reduced mucin content in stomach and small intestine were observed in rats receiving 5-FU alone. In the stomach, all antisecretory drugs caused the protective effects against 5-FU-induced mucosal injury and alleviation of the decreased mucin accumulation. In the jejunum and ileum, lafutidine, but neither omeprazole nor lansoprazole, ameliorated the 5-FU-induced mucosal damage and decreased mucin accumulation. Conclusion Lafutidine could offer the possibility of more effective prevention of CT-induced mucositis through the activation of GI mucus cells. for 30 min at 4C, the supernatant was collected and an aliquot was applied to a Bio-Gel A-1.5 m column, and eluted with the Triton-Tris buffer. The void volume portion (Fr-1) monitored by hexose measurement was collected as mucin. Hexose content material in this portion was measured from the phenol-sulfuric acid method using galactose as the standard. Mucin content (Fr-1 hexose value) was indicated as micrograms of hexose per cells. Statistical analysis The difference in the mean ideals among the 6-Maleimido-1-hexanol organizations was analyzed by one-way ANOVA with Scheffe’s test; a = 6C9 (each group); * 0.05. Changes in immunoreactivity and mucin content material of the small-intestinal mucosa Number 3 shows the morphological changes in the small-intestinal mucosa after treatments. In the control rats, immunohistochemical reactivity for PGM34 could be recognized in the goblet cells, as well as the surface mucus gel coating, in the jejunum and ileum (Number 3A, F). As demonstrated in Number 3B and G, 5-FU treatment caused a marked decrease in villus height and a remarkable reduction in the number of PGM34-positive goblet cells. In the animals treated with a combination of 5-FU and lafutidine, significant observable damage could rarely become found in the sections of the jejunal or ileal mucosa (Number 3E, J), whereas neither omeprazole (Number 3C, H) nor lansoprazole (Number 3D, I) was shown to prevent the 5-FU-induced intestinal mucosal damage. Open in a separate window Number 3 Immunostaining of the rat jejunal (ACE) and ileal (FCJ) mucosae with anti-mucin monoclonal antibody PGM34. Small-bowel cells were from control rats (A, F), rats treated with 5-fluorouracil (5-FU) only (B, G), rats treated with omeprazole (Ome)+5-FU (C, H), rats treated with lansoprazole (Lan)+5-FU (D, I), and rats treated with lafutidine (Laf)+5-FU (E, J). Notice that goblet cells in the jejunum and ileum display positive staining with PGM34. Initial magnification 25. Number 4 shows the assessment of the effects of the anti-ulcer medicines within the small-intestinal mucin material in the 5-FU-induced mucosal damage. A decrease in the mucin content material of the jejunum and ileum was observed after treatment with 5-FU (29.6% and 42.9% 6-Maleimido-1-hexanol of the control mucin content, respectively). Lafutidine pretreatment significantly inhibited the 5-FU-induced mucin reduction in the jejunum and ileum mucin (75.8% and 6-Maleimido-1-hexanol 66.1% of the control mucin, respectively), whereas no significant change could be recognized in the mucin content in the small intestine from the 5-FU treatment with either omeprazole or lansoprazole. Open in a separate window Number 4 Influence of acid antisecretory THSD1 agents within the jejunal (A) and ileal (B) mucin build up in the 5-FU-induced small-bowel mucosal damage. Fr-1 hexose ideals related to mucin content material are indicated as micrograms of hexose per rat and represent meansSD. Abbreviations: 5-FU = 5-fluorouracil; Ome = omeprazole; Lan 6-Maleimido-1-hexanol = lansoprazole; Laf = lafutidine. = 6C9 (each group); * em p /em 0.05. Conversation Using the original anti-mucin mAbs RGM21 and RGM26, we shown the protective effects of three anti-ulcer medicines, omeprazole, lansoprazole, and lafutidine, against 5-FU-induced gastric mucosal injury of the rat. From your randomized controlled studies, Sartori et al. [4,5] recorded that the strong and long term suppression of gastric acid secretion by omeprazole was effective in avoiding and reducing CT-induced gastroduodenal mucosal injury, suggesting an important prophylactic role of the inhibition of acid secretion. Both lansoprazole and lafutidine possess a potent and long-lasting gastric antisecretory effect in humans [6,7]. In the rat models, each.